companies / abzymetx-com
Generated UTC · publication cutoff 2026-11-09
Insufficient cited evidence for a two-sentence summary.
verified=2026-05-06 json
| total_raised | 1,657,9941.7M | ○ |
|---|---|---|
| founded | 2017 | |
| hq | Pottstown, Pennsylvania, USA | |
| industry | unknown | |
| stage | null |
Abzyme Therapeutics develops modular single-domain VHH antibody fragments for immunotherapy using a proprietary yeast-display discovery platform. It serves biopharma partners needing antibodies optimized for affinity, solubility, and developability. Its differentiator is a self-diversifying library that screens these properties in real time.
No cited completed company acquisition recorded.
Dated disclosures. Customer relationships and classifications are historical; ARR is separate from revenue.
No cited disclosure recorded: named customer, disclosed revenue, ARR, count, B2B / B2C, sector, go-to-market.
No cited valuation with an explicit basis is recorded.
Historical post-money / actual annual or stated TTM revenue. Same currency; economic valuation date within 90 days of revenue period end, inclusive. No FX, ARR, annualized revenue, estimates or projections. Conflicts and ambiguous ties are withheld.
No qualifying pair recorded.
| date | type | amount | lead | src |
|---|---|---|---|---|
| 2024-01-01 | grant | 1,657,9941.7M | null | ○ |
Cloudflare, WordPress, Genesis theme, Slider Revolution 6.7.55, jQuery Migrate 3.4.1, WP Rocket, PHP, MySQL, jquery 3.
| fact | status | src |
|---|---|---|
| Grant, $1.7M | attributed | ○ |
| existence | self-reported | WEB |
| description | self-reported | WEB |